As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis. by Cappelli, F et al.
20
13
http://informahealthcare.com/amy
ISSN: 1350-6129 (print), 1744-2818 (electronic)
Amyloid, Early Online: 1–2
! 2013 Informa UK Ltd. DOI: 10.3109/13506129.2013.808993
LETTER TO THE EDITOR
As we cannot afford to renounce to new generation echocardiography
in systemic amyloidosis
Francesco Cappelli1,2, Stefano Perlini3, Paola Attana`4, Gabriele Ciuti5, Francesco Salinaro3, and Federico Perfetto2
1Intensive Cardiac Care Unit, Heart and Vessel Department, University of Florence, Florence, Italy, 2Regional Amyloid Center, AOU Careggi, Florence,
Italy, 3Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy, 4Florence Heart and Vessels
Department, University of Florence, Florence, Italy, and 5Department of Internal Medicine, University of Florence, Florence, Italy
It was with great interest that we read the recent report by
Granstam et al. regarding multimodal characterization of
amyloid patients [1]. In their article, the authors summarized
the major characteristics of cardiac amyloidosis patients using
ECG, standard echocardiography and right heart catheteriza-
tion parameters.
Indeed two-dimensional (2D), M-mode, and Doppler
echocardiography still play a major role in the assessment
of amyloid deposition in the heart. However, diagnosis of
cardiac amyloidosis merely based on these conventional
ultrasonographic techniques is only possible when the disease
has already reached a relatively advanced stage, where almost
irreversible functional and structural myocardial changes have
occurred [2]. According to the consensus criteria of the
International Society of Amyloidosis, diagnosis should also
be based on the elevation of cardiac biomarkers [3].
As to the imaging techniques, in patient with systemic
amyloidosis tissue Doppler (TDI) derived strain and strain
rate could assess regional myocardial deformation by detect-
ing left ventricular (LV) longitudinal systolic function
abnormalities before LV wall thickness increase and symp-
toms onset [4].
Moreover, 2D speckle-tracking echocardiography has
nowadays enabled the assessment of a particular behavior of
LV motion that can be defined as twisting/untwisting.
Porciani and coworkers demonstrated that LV twisting and
untwisting motions are increased in patients with AL
amyloidosis and no evidence of cardiac involvement, while
these motions are reduced in patients with evident amyloid-
osis cardiac involvement [5,6]. This finding suggests that
early in the disease, impaired LV relaxation induces a
compensatory mechanism based on LV twisting/untwisting
motion increase. Such a peculiar behavior that can be detected
only by 2D speckle strain echocardiography, can be useful in
diagnosing early cardiac involvement in patient with systemic
amyloidosis.
Furthermore, recent reports have demonstrated as both
TDI derived strain and 2D speckle-tracking echocardiography
can be usefully applied to right ventricular (RV) evaluation in
patient with amyloidosis. Bellavia et al. showed that patients
with AL amyloidosis and apparently normal 2D and Doppler
echocardiography results may present an early impairment
of RV longitudinal systolic function, primarily detectable
by TDI systolic strain of the basal segment of the RV free
wall [7].
In the same line, our group demonstrated that in similar
patients, a mean RV longitudinal 2D speckle-tracking strain
less negative than –17% identifies a cohort of patients with
marked RV dysfunction and a high risk of death. In addition,
at multivariate analysis RV longitudinal strain was the only
echocardiographic predictor of prognosis [8]. This adds on a
previous report by Ghio and coworkers [9] on tricuspid
annular plane systolic excursion (TAPSE) as a marker of RV
systolic dysfunction. In our opinion these studies strongly
demonstrate that by these advanced techniques, early func-
tional impairment in cardiac amyloidosis may be detectable
when the results of standard echocardiography are still normal
or inconclusive.
Furthermore, if a diagnosis of systemic amyloidosis
has already been made on the setting of haematological,
nephrological or neurological impairment, the role of the
cardiological evaluation becomes essential in confirming
or excluding a possible cardiac involvement, which has a
profound impact on patient’s prognosis as well as on the
therapeutical approach. In patients who do not have overt
cardiological disease, diagnosis of cardiac amyloid involve-
ment is particularly challenging. Given that early diagnosis of
cardiac amyloidosis should be the primary goal of the
cardiologist, in such a situation we believe that a compre-
hensive cardiac amyloidosis evaluation should be integrated
by the use of 2D speckle strain echocardiography or at
least by the support of a TDI derived strain imaging
assessment. Indeed, the possibility to detect a very early
cardiac involvement with more sensitive diagnostic tools
could be very helpful in improving diagnosis, in stratifying
prognosis and in guiding the therapeutic strategy in amyloid-
osis patients.
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